Subscribe to MDT Magazine News

Microchips moves osteoporosis device into trial

February 3, 2011 8:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Some 18 years after MIT professor Robert Langer first envisioned using an implantable reservoir as a drug delivery device, one of his companies, MicroCHIPS Inc. of Bedford, announced today that it is initiating a clinical study of a device that delivers a peptide over the course of months...

Carrot Medical Reports 2010 Growth in Sales and Financing, Optimism for 2011

February 3, 2011 7:33 am | by Bio-Medicine.Org | Comments

BOSTON, Feb. 3, 2011 /- Carrot Medical, a leading designer of integrated medical imaging display systems, has announced results for 2010. During the year, Carrot Medical achieved significant growth in sales, an expansion of sales channels and secured additional private financing. Carrot...


Curemark Hosts New York Senator Kirsten Gillibrand

February 3, 2011 7:32 am | by Bio-Medicine.Org | Comments

RYE, N.Y., Feb. 3, 2011 /- Curemark, LLC , ( ), a drug research and development company focused on the treatment of neurological diseases, recently hosted New York Senator Kirsten Gillibrand as she announced a new proposal to spur innovation and job creation, locally and...


Hospira Announces FDA Approval of Topotecan Injection

February 3, 2011 7:32 am | by Bio-Medicine.Org | Comments

LAKE FOREST, Ill., Feb. 3, 2011 /- Hospira, Inc. (NYSE: HSP ), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of Topotecan Injection, the first solution formulation of the oncology drug approved in the United...


SkinMedica Launches Redness Relief CalmPlexâ„¢

February 3, 2011 7:32 am | by Bio-Medicine.Org | Comments

CARLSBAD, Calif., Feb. 3, 2011 /- SkinMedica, Inc., the fastest-growing professional skin care company in the United States, today announced that it is introducing a new, fast-acting anti-redness product, Redness Relief CalmPlex™—the biggest innovation in redness in over two...


Dendreon Announces Exercise and Closing of Overallotment Option

February 3, 2011 7:32 am | by Bio-Medicine.Org | Comments

SEATTLE, Feb. 3, 2011 /- Dendreon Corporation (Nasdaq: DNDN ) today announced that the underwriter in its previously announced public offering of 2.875% convertible senior notes due January 15, 2016 (the "Notes") exercised and closed on its overallotment option in full to purchase an...


Missouri Baptist Medical Center - Only Non-Teaching Hospital in Region to Offer Colorectal Cancer Patients Robotic Surgery

February 3, 2011 7:30 am | by Bio-Medicine.Org | Comments

ST. LOUIS, Feb. 3, 2011 /- Missouri Baptist Medical Center now provides patients with a new, minimally invasive surgical treatment option for colorectal cancer – robotic surgery with the da Vinci®-S™ Surgical System.  Eric D. Lederman, MD, a board certified general...


Summary Box: CVS Caremark 4th-quarter profit slips

February 3, 2011 6:45 am | by The Associated Press | Comments

THE RESULTS: CVS Caremark Corp. said its fourth-quarter profit slipped because of business lost by its Caremark pharmacy benefits management unit. The company expects better results in 2011, but said operating income at Caremark will continue to decline.THE OUTLOOK: Caremark's income is expected to...


CVS Caremark 4Q profit falls 2 percent

February 3, 2011 5:45 am | by The Associated Press | Comments

Drugstore chain and pharmacy benefits manager CVS Caremark Corp. said Thursday that its profit fell 2 percent in the fourth quarter on lower revenue because of client losses and fewer Medicare prescription drug program members.The company also offered an estimate for adjusted earnings for this...

Lilly and JDRF partner to fund regenerative medicine research in type 1 diabetes

February 3, 2011 5:36 am | by EurekAlert | Comments

(Juvenile Diabetes Research Foundation International) Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing...


Adapting technology to elderly people

February 3, 2011 5:36 am | by EurekAlert | Comments

(EUREKA) With the numbers of people aged 65 and over growing, the costs to the state to care for or assist them are set to continue rising across the European Union. With this backdrop, two companies have combined their differing expertise, with the help of Eureka funding, to...


Concert Pharmaceuticals, Walter Reed partner on seizure treatment

February 3, 2011 5:32 am | by Mass High Tech: The Journal of New England Technology | Comments

Concert Pharmaceuticals Inc. today announced that it has signed an agreement to work with the Walter Reed Army Institute of Research to conduct preclinical testing of a Concert drug compound in treating seizures stemming from traumatic brain injuries.


Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine(2)

February 3, 2011 5:31 am | by Bio-Medicine.Org | Comments

WORCESTER, Mass., Feb. 3, 2011 /- Generex Biotechnology Corporation ( ) (OTC Bulletin Board: GNBT ), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. ( ), announced today that Antigen Express has received a...


Mednax 4Q profit rises 9 percent on revenue

February 3, 2011 4:45 am | by The Associated Press | Comments

National physician group Mednax Inc. said Thursday that its fourth-quarter profit rose 9 percent on a boost in revenue.Mednax earned $53.8 million, or $1.12 per share, up from $50.4 million, or $1.07 per share, in the same quarter last year. Revenue rose 10.6 percent to $368.5 million from...

Discovery May Lead to Turning Back the Clock on Ovarian Cancer

February 3, 2011 4:38 am | by Georgia Tech Institute of Technology | Comments

Cancer researchers have discovered that a type of regulatory RNA may be effective in fighting ovarian cancer. This new discovery may allow physicians to turn back the clock of the tumor's life cycle to a phase where traditional chemotherapy can better do its job.


You may login with either your assigned username or your e-mail address.
The password field is case sensitive.